Karyopharm Therapeutics Inc Asset Resilience Ratio

Latest as of June 2026: 9.10%

Karyopharm Therapeutics Inc asset resilience ratio. Karyopharm Therapeutics Inc (KPTI) has an Asset Resilience Ratio of 9.10% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Karyopharm Therapeutics Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.

Liquid Assets

$10.12 Million
Cash + Short-term Investments

Total Assets

$111.32 Million
All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of Karyopharm Therapeutics Inc (2013–2025)

Asset resilience ratio of Karyopharm Therapeutics Inc from 2013 to 2025. This chart shows how Karyopharm Therapeutics Inc's Asset Resilience Ratio has changed over time. Read Karyopharm Therapeutics Inc balance sheet liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Karyopharm Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Karyopharm Therapeutics Inc assets under control.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $10.12 Million 9.1%
Total Liquid Assets $10.12 Million 9.10%

Asset Resilience Insights

  • Limited Liquidity: Karyopharm Therapeutics Inc maintains only 9.10% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Karyopharm Therapeutics Inc Industry Peers by Asset Resilience Ratio

Compare Karyopharm Therapeutics Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
GT Biopharma Inc
NASDAQ:GTBP
Biotechnology 0.00%
Kura Oncology Inc
NASDAQ:KURA
Biotechnology 76.35%
Sprint Bioscience AB
ST:SPRINT
Biotechnology 77.81%
Herantis Pharma Oyj
HE:HRTIS
Biotechnology 89.18%
Suzhou Fushilai Pharmaceutical Co. Ltd.
SHE:301258
Biotechnology 45.84%
Inventiva S.A
PA:IVA
Biotechnology 52.73%
Sinocelltech Group Ltd
SHG:688520
Biotechnology 5.27%
Argenica Therapeutics Ltd
AU:AGN
Biotechnology 0.52%

Karyopharm Therapeutics Inc Asset Resilience Ratio by Year (2013–2025)

Karyopharm Therapeutics Inc asset resilience ratio by year from 2013 to 2025. The table below shows the annual Asset Resilience Ratio data for Karyopharm Therapeutics Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 2.96% $3.20 Million $108.42 Million -25.17pp
2024-12-31 28.12% $46.24 Million $164.42 Million -29.78pp
2023-12-31 57.90% $139.21 Million $240.44 Million +18.04pp
2022-12-31 39.86% $142.78 Million $358.17 Million +27.37pp
2021-12-31 12.50% $38.16 Million $305.31 Million -39.67pp
2020-12-31 52.17% $163.32 Million $313.05 Million +7.05pp
2019-12-31 45.12% $133.10 Million $294.96 Million -16.48pp
2018-12-31 61.60% $210.18 Million $341.19 Million +18.63pp
2017-12-31 42.97% $77.47 Million $180.29 Million -1.32pp
2016-12-31 44.29% $79.89 Million $180.38 Million -10.15pp
2015-12-31 54.43% $117.28 Million $215.44 Million +29.42pp
2014-12-31 25.01% $55.12 Million $220.34 Million --
2013-12-31 0.00% $0.00 $158.23 Million --
pp = percentage points

About Karyopharm Therapeutics Inc

NASDAQ:KPTI USA Biotechnology
Market Cap
$2.54 Million
Market Cap Rank
#25845 Global
#5442 in USA
Share Price
$0.11
Change (1 day)
-83.08%
52-Week Range
$0.11 - $10.67
All Time High
$27.72
About

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exporti… Read more